7 completed, 1 terminated. 8 Phase 1.
By phase and status
Follow Diagnostic Imaging: new trials by email Literature Review of Diagnostic Imaging trials Research Report on Diagnostic Imaging
Trials (filtered) newest first · largest first
All 8 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.
BAY86-9596 - Diagnostic Imaging | Phase 1 | Completed | 24 | 2011-05-01 | 2013-01-21 |
PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers
BAY1075553 - Diagnostic Imaging | Phase 1 | Completed | 14 | 2011-02-01 | 2013-01-21 |
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers
Bombesin (68Ga) labeled (BAY86-7548) - Diagnostic Imaging | Phase 1 | Completed | 19 | 2010-11-01 | 2013-01-21 |
Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers
BAY1006578 - Diagnostic Imaging | Phase 1 | Completed | 24 | 2010-06-01 | 2013-01-21 |
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations
BAY86-9596, Fludeoxyglucose (18F)-IBA - Diagnostic Imaging | Phase 1 | Completed | 35 | 2010-05-01 | 2026-10-26 |
Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation
BAY94-9392 - Diagnostic Imaging, Neoplasms | Phase 1 | Completed | 46 | 2010-04-01 | 2026-10-26 |
Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers
F-18 DPA-714 (BAY85-8102) - Diagnostic Imaging | Phase 1 | Completed | 22 | 2009-10-01 | 2013-07-31 |
Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers
BAY86-4367 - Diagnostic Imaging | Phase 1 | Terminated | 16 | 2009-09-01 | 2014-06-26 |
Narrower conditions
Neoplasms (6) · Alzheimer Disease (2) · Inflammation (2) · Prostatic Neoplasms (1)
Broader conditions
Brain Diseases (2) · Central Nervous System Diseases (2) · Dementia (2) · Mental Disorders (2) · Nervous System Diseases (2) · Neurocognitive Disorders (2) · Neurodegenerative Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Tauopathies (2) · Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Male Urogenital Diseases (1) · Neoplasms by Site (1)
Interventions
BAY 86-4367 (1) · BAY 86-7548 (1) · Bombesin (1) · Product Labeling (1)
Sponsors
Lantheus Biosciences Ltd. (6) · Bayer (2)
Countries
Finland (3) · Germany (3) · Switzerland (3) · Netherlands (2) · United States (2) · Austria (1) · Singapore (1) · South Korea (1) · Sweden (1)
Results publications
PMID 32694158
NIH funding
2009 (3), 2008 (2)